Research programme: ras-selective modified adenoviruses - Oncolytics Biotech

Drug Profile

Research programme: ras-selective modified adenoviruses - Oncolytics Biotech

Alternative Names: Ras-selective modified adenoviruses - Oncolytics Biotech

Latest Information Update: 14 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncolytics Biotech; The Catalan Institute of Oncology
  • Developer Oncolytics Biotech
  • Class Viruses
  • Mechanism of Action Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 24 Oct 2008 Pharmacodynamic data from a preclinical study in Malignant melanoma presented at the 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 29 Sep 2003 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 05 Aug 2003 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top